Altitude Online: The Business of Neuroscience & Psychedelics

"It is not the thing itself that disturbs you, but your judgment about it — and it is in your power to wipe out that judgment now." — Marcus Aurelius

Policy

The Psychedelic Money Graveyard: Renames, Reverse Mergers, and the Companies That Didn't Make It

Behind the rankings is a much messier story — a wave of renames, a wave of consolidation, and a genuine graveyard of companies that raised real money and still didn't survive.

Nathan Richardson • Sep 17, 2026

Policy

The Psychedelic Money Rankings: $11 Billion Public, $1.6 Billion Private, $140 Million From Governments

Wellness

Permafried

Policy Aug 31, 2026

Ibogaine's Flagship Drug Hit a Cardiac Signal and a Lawsuit. A Different Drug Is Now Leading.

Policy Aug 28, 2026

Ketamine Has More Patents Than Any Compound We Track. So Why Isn't Big Pharma More Interested?

Policy Aug 28, 2026

Altitude Intelligence Brief: Who's Actually Making Money on Depression, Anxiety, and PTSD

Policy Aug 26, 2026

Psychedelics in Uniform: What the Military Did to Soldiers, and What the VA Is Now Asking of Veterans

Policy Aug 26, 2026

LSD Has 14 Patents in Our Tracker. The Company Closest to Approval Owns One.

Policy Aug 24, 2026

The 5-MeO-DMT Patent Race Has a Twist: The Clinical Leader Barely Owns Any of It

Policy Aug 20, 2026

I Thought I'd Walked Into a Retirement Community. What I Found Was a Masterclass in How the Brain Stays Young

Research Jul 29, 2026

Eli Lilly Just Paid $3.8 Billion for the Same Molecule People Get From a Toad

Personal Story Jul 31, 2026

Holding Your Breath On Purpose

Research Jul 29, 2026

Everyone Knows Which Pill They Got. The FDA Just Said What To Do About It.

Personal Story Apr 4, 2026

Love Yourself Five Times: How Psilocybin Changed My Life

Psychedelic Medicine Jul 7, 2026

The Next Psilocybin Question Is Not Hype. It Is Evidence, Timing, and Review.

Neuroscience Mar 28, 2026

Fear Is Not a Character Flaw. It's Architecture.

Neuroscience Mar 21, 2026

Three Paths to a Healthier Brain: Learning, Meditation, and Psychedelics

Policy Mar 14, 2026

Clinical vs. Consumer: Navigating the New Psilocybin Landscape

Editorial Mar 7, 2026

What Is Evidence-Based Healing? A Guide to Altitude Global's Standards

Personal Story Feb 28, 2026

The God Molecule and the Spilled Milk

Research Feb 14, 2026

The Clinical Revolution: Psilocybin and 5-MeO-DMT Move from Underground to Evidence-Based Medicine

Latest News

See All

Definitions Sep 17, 2026

Definium's LSD Compound Just Posted Its Second Positive Phase 3 Trial for Anxiety

Regulatory Sep 15, 2026

Over 1,800 People Registered for the FDA's Psychedelic Drugs Hearing. Here's What They Said.

Definitions Sep 15, 2026

Definition Day: DMT & Bicycle Day

Regulatory Sep 14, 2026

Senior FDA Officials Just Laid Out Their New Framework for Psychedelic Drugs — in NEJM

Psychedelics Sep 11, 2026

New on Altitude: $11 Billion Public, $1.6 Billion Private, $140 Million From Governments

Regulatory Sep 11, 2026

Puerto Rico Just Became the Latest U.S. Territory to Explore a Psychedelic Research Pilot

Definitions Sep 10, 2026

Calm

Sleep more. Stress less. Live better. The #1 app for sleep, meditation and relaxation.

Shop Now — $69.99

Encyclopedia

Mindset and environment shaping the experience.

Example: "Setting" isn't just ambiance — our reporting on overseas clinic safety found that poor setting (unscreened staff, absent medical oversight, patients dosed without preparation) was a common thread across the worst documented outcomes, not just an aesthetic afterthought.

See All Terms

Aa-Zz

Join the Circle

Access the inner sanctum of Altitude. Weekly digests on neuroscience, early access to retreat bookings, and exclusive product drops.

Free Membership • Unsubscribe Anytime